FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2111337498> ?p ?o ?g. }

• W2111337498 endingPage "62" @default.
• W2111337498 startingPage "1853" @default.
• W2111337498 abstract "The efficacy control for the treatment of bone metastases in breast cancer is difficult and usually initiated later and with longer time between treatment cycles than the restaging of visceral or soft tissue metastases. The amino-terminal propeptide (PINP) of type I collagen as a biochemical indicator of bone turnover might facilitate early and valid disease surveillance. The utility of total PINP was investigated in metastatic breast cancer patients, with or without bone metastases (for monitoring of therapy). The results were compared to the established markers, osteocalcin and beta-carboxyterminal telopeptide (CTX) or crosslaps concentration.Baseline serum samples of 51 patients with metastastic breast cancer under chemotherapy were investigated. In total, 38 patients had been diagnosed with bone metastases while 13 had no evidence of metastastic spread to the bone. All the patients with bone spread received bisphosphonates in addition to systemic chemotherapy and/or antibody therapy or hormonal treatment. Osteocalcin, CTX and PINP levels were measured on an Elecsys 2010 analyzer (electrochemiluminescence immunoassay--ECLIA). The normal cut-off values were: osteocalcin < 41.3 pg/ml, CTX < 1008 pg/ml and PINP < 95 ng/ml. Based on overall treatment outcome, the patients were grouped as responders (CR/PR), with stable disease (SD) or displaying primary progression (PD).The baseline levels of PINP were significantly higher in patients with bone metastases (median: 92.8 ng/ml) than in those without (median: 63.2 ng/ml, p = 0.044). Patients with more than seven bone metastases had significantly higher PINP levels (median: 149.7 ng/ml) than those with fewer than seven (median: 67.6 ng/ml, p = 0.04). Significant differences were also found for osteocalcin and CTX, at p = 0.02 and p = 0.04, respectively, although the median levels remained under the normal cut-off levels. In terms of response assessment of bone spread, the PINP concentrations decreased in responders from 194.3 ng/ml to 100.4 ng/ml (p = 0.23). In patients with SD, PINP remained at the same level of approximately 70 ng/ml (p = 0.16), but increased in patients with PD from 83.4 ng/ml to 176.5 ng/ml (p = 0.14). These trends rather than statistical difference were probably due to the limited patient cohort. No differences were found for the serum concentrations of PINP, CTX and osteocalcin between post- and pre-menopausal women.The PINP levels of the osseous metastatic breast cancer patients were elevated at baseline in comparison to those without bone involvement; the levels correlated to the number of bone metastases but were independent of the menopausal status. Thus, the levels of PINP under therapy might correlate with the response to therapy. Osteocalcin and CTX did not show similar sensitivity for the surveillance of bone metastases." @default.
• W2111337498 created "2016-06-24" @default.
• W2111337498 creator A5018668085 @default.
• W2111337498 creator A5035775338 @default.
• W2111337498 creator A5041022158 @default.
• W2111337498 creator A5059829542 @default.
• W2111337498 creator A5081716847 @default.
• W2111337498 creator A5083429020 @default.
• W2111337498 date "2007-07-26" @default.
• W2111337498 modified "2023-10-01" @default.
• W2111337498 title "The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer." @default.
• W2111337498 cites W129830104 @default.
• W2111337498 cites W1482712481 @default.
• W2111337498 cites W1812151559 @default.
• W2111337498 cites W1932008746 @default.
• W2111337498 cites W1938350058 @default.
• W2111337498 cites W1959778450 @default.
• W2111337498 cites W1977510477 @default.
• W2111337498 cites W1981412921 @default.
• W2111337498 cites W2014006626 @default.
• W2111337498 cites W2035698223 @default.
• W2111337498 cites W2046750802 @default.
• W2111337498 cites W2052804491 @default.
• W2111337498 cites W2403507475 @default.
• W2111337498 cites W2419565413 @default.
• W2111337498 cites W96826905 @default.
• W2111337498 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17649784" @default.
• W2111337498 hasPublicationYear "2007" @default.
• W2111337498 type Work @default.
• W2111337498 sameAs 2111337498 @default.
• W2111337498 citedByCount "15" @default.
• W2111337498 countsByYear W21113374982013 @default.
• W2111337498 countsByYear W21113374982014 @default.
• W2111337498 countsByYear W21113374982015 @default.
• W2111337498 countsByYear W21113374982016 @default.
• W2111337498 countsByYear W21113374982019 @default.
• W2111337498 countsByYear W21113374982021 @default.
• W2111337498 countsByYear W21113374982022 @default.
• W2111337498 crossrefType "journal-article" @default.
• W2111337498 hasAuthorship W2111337498A5018668085 @default.
• W2111337498 hasAuthorship W2111337498A5035775338 @default.
• W2111337498 hasAuthorship W2111337498A5041022158 @default.
• W2111337498 hasAuthorship W2111337498A5059829542 @default.
• W2111337498 hasAuthorship W2111337498A5081716847 @default.
• W2111337498 hasAuthorship W2111337498A5083429020 @default.
• W2111337498 hasConcept C121608353 @default.
• W2111337498 hasConcept C125870589 @default.
• W2111337498 hasConcept C126322002 @default.
• W2111337498 hasConcept C126894567 @default.
• W2111337498 hasConcept C131075544 @default.
• W2111337498 hasConcept C134018914 @default.
• W2111337498 hasConcept C143998085 @default.
• W2111337498 hasConcept C160160445 @default.
• W2111337498 hasConcept C170033053 @default.
• W2111337498 hasConcept C181199279 @default.
• W2111337498 hasConcept C185592680 @default.
• W2111337498 hasConcept C2775930923 @default.
• W2111337498 hasConcept C2776694085 @default.
• W2111337498 hasConcept C2777783956 @default.
• W2111337498 hasConcept C530470458 @default.
• W2111337498 hasConcept C55493867 @default.
• W2111337498 hasConcept C71924100 @default.
• W2111337498 hasConcept C90924648 @default.
• W2111337498 hasConceptScore W2111337498C121608353 @default.
• W2111337498 hasConceptScore W2111337498C125870589 @default.
• W2111337498 hasConceptScore W2111337498C126322002 @default.
• W2111337498 hasConceptScore W2111337498C126894567 @default.
• W2111337498 hasConceptScore W2111337498C131075544 @default.
• W2111337498 hasConceptScore W2111337498C134018914 @default.
• W2111337498 hasConceptScore W2111337498C143998085 @default.
• W2111337498 hasConceptScore W2111337498C160160445 @default.
• W2111337498 hasConceptScore W2111337498C170033053 @default.
• W2111337498 hasConceptScore W2111337498C181199279 @default.
• W2111337498 hasConceptScore W2111337498C185592680 @default.
• W2111337498 hasConceptScore W2111337498C2775930923 @default.
• W2111337498 hasConceptScore W2111337498C2776694085 @default.
• W2111337498 hasConceptScore W2111337498C2777783956 @default.
• W2111337498 hasConceptScore W2111337498C530470458 @default.
• W2111337498 hasConceptScore W2111337498C55493867 @default.
• W2111337498 hasConceptScore W2111337498C71924100 @default.
• W2111337498 hasConceptScore W2111337498C90924648 @default.
• W2111337498 hasIssue "4A" @default.
• W2111337498 hasLocation W21113374981 @default.
• W2111337498 hasOpenAccess W2111337498 @default.
• W2111337498 hasPrimaryLocation W21113374981 @default.
• W2111337498 hasRelatedWork W1517801548 @default.
• W2111337498 hasRelatedWork W1812151559 @default.
• W2111337498 hasRelatedWork W1952385262 @default.
• W2111337498 hasRelatedWork W1959778450 @default.
• W2111337498 hasRelatedWork W1988086821 @default.
• W2111337498 hasRelatedWork W1998765212 @default.
• W2111337498 hasRelatedWork W2014006626 @default.
• W2111337498 hasRelatedWork W2057502240 @default.
• W2111337498 hasRelatedWork W2060700125 @default.
• W2111337498 hasRelatedWork W2080658541 @default.
• W2111337498 hasRelatedWork W2115962082 @default.
• W2111337498 hasRelatedWork W2126186971 @default.
• W2111337498 hasRelatedWork W2127670800 @default.

• next